logo
  

Court Rules In Favor Of LPKF In Patent Infringement Litigation With Motorola

Specialty mechanical engineering company LPKF laser and electronics AG (LPKFF.OB) said that the Mannheim Regional Court ruled in favor of LPKF and against Motorola in the legal dispute about patent infringement.

LPKF has won a preliminary victory in the legal dispute concerning the infringement of the patent for Laser Direct Structuring or LDS.

On July 8, 2014, the Mannheim Regional Court ordered Motorola Deutschland and Motorola
Mobility USA to refrain from selling cell phones in Germany that infringe the patent and ordered Motorola Deutschland to recall all cell phones that infringe the patent from commercial customers.

Moreover, the court determined that both defendants must pay compensation. The judgment may be appealed.

The LDS process patented by LPKF is increasingly used to produce complex antennas for cell phones or tablet PCs.

In 2013 the patent was declared invalid for the People's Republic of China. LPKF subsequently submitted an application to reopen proceedings, which China's Supreme People's Court accepted for review. In addition, LPKF is systematically taking action against cell phone manufacturers that bring counterfeit LDS components into circulation outside China.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
Follow RTT